Genentech to pursue Lucentis as treatment for diabetic retinopathy

Genentech has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Lucentis for the treatment of diabetic retinopathy. “Diabetic retinopathy is the leading cause of new blindness in working-aged Americans. Our hope is that having Lucentis approved as the first ocular treatment for diabetic retinopathy in the U.S. will have a positive impact on patients who have diabetic retinopathy,” Jason Ehrlich, MD, PhD, Genentech group medical director, said in an interview with Ocular Surgery News.